Search hospitals > Pennsylvania > Bethlehem
Lehigh Valley Hospital - Muhlenberg
Claim this profileBethlehem, Pennsylvania 18017
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Breast Cancer
Conducts research for Tumors
Conducts research for Lung Cancer
261 reported clinical trials
8 medical researchers
Summary
Lehigh Valley Hospital - Muhlenberg is a medical facility located in Bethlehem, Pennsylvania. This center is recognized for care of Cancer, Leukemia, Breast Cancer, Tumors, Lung Cancer and other specialties. Lehigh Valley Hospital - Muhlenberg is involved with conducting 261 clinical trials across 530 conditions. There are 8 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Leukemia
Global LeaderStage II
CD5 positive
Stage I
Top PIs
Tareq Al BaghdadiSaint Joseph Mercy Hospital7 years of reported clinical research
Expert in Cancer
Expert in Tumors
69 reported clinical trials
127 drugs studied
Christopher M. Reynolds, MDSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
45 reported clinical trials
99 drugs studied
Philip J. StellaSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
38 reported clinical trials
89 drugs studied
Elie G. DibSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Cancer
Studies Multiple Myeloma
34 reported clinical trials
94 drugs studied
Clinical Trials running at Lehigh Valley Hospital - Muhlenberg
Breast Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Bladder Carcinoma
Colorectal Cancer
Gastric Cancer
Multiple Myeloma
Rectal Cancer
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Lehigh Valley Hospital - Muhlenberg?
Lehigh Valley Hospital - Muhlenberg is a medical facility located in Bethlehem, Pennsylvania. This center is recognized for care of Cancer, Leukemia, Breast Cancer, Tumors, Lung Cancer and other specialties. Lehigh Valley Hospital - Muhlenberg is involved with conducting 261 clinical trials across 530 conditions. There are 8 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.